TITLE

HIDDEN TRUTH: THE PERILS AND PROTECTION OF OFF-LABEL DRUG AND MEDICAL DEVICE PROMOTION

AUTHOR(S)
Conko, Gregory
PUB. DATE
January 2011
SOURCE
Health Matrix: Journal of Law-Medicine;Winter2011, Vol. 21 Issue 1, p149
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the rule of off-label prescribing and its role in the practice of medicine in the U.S. It discusses the evolution of the Food, Drug and Cosmetics Act and the role of the Food and Drug Administration (FDA) in the device and drug approval process. It highlights the range of permissible commercial speech regulation and examines the constitutionality of off-label speech limitations.
ACCESSION #
65264706

 

Related Articles

  • New formulations.  // Formulary;May99, Vol. 34 Issue 5, p392 

    Reports directed formulations of several drugs approved by the Food and Drug Administration in the United States. Plant-derived formulation of synthetic conjugated estrogens for menopause symptoms; Protein formulation of hepatitis B immune globulin; Intravenous formulation of itraconazole for...

  • FDA approves label change for nevirapine.  // AIDS Alert;Aug2008, Vol. 23 Issue 8, p91 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the labeling changes of the Viramune (nevirapine) tablets and oral solution along with its various updates on June 24, 2008.

  • MED WATCH: FDA Warns Against Lidocaine Solution for Teething Pain.  // American Family Physician;8/15/2014, Vol. 90 Issue 4, p210 

    The article reports on the safety announcement issued by the U.S. Food and Drug Administration (FDA) regarding the prescription of oral viscous lidocaine for the treatment of teething pain in young children.

  • User fees help speed brand Rx approvals. Conlan, Michael F. // Drug Topics;1/5/98, Vol. 142 Issue 1, p19 

    Focuses on the United States Food and Drug's (FDA) approval of brand prescriptions (Rx). Impact user fees has on the speedy approval of these drugs; Reference to the Prescription Drug User Fee Act; Comments from Michael A. Friedman, lead deputy commissioner of FDA; Benefits consumers would...

  • FDA panel votes against new rules on DXM meds.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p27 

    The article reports on the opposition of the advisory panel of the U.S. Food and Drug Administration (FDA) regarding the prescription requirements for cough medicines containing dextromethorphan (DXM) following the report from the Drug Enforcement Agency (DEA) on the abuse of over-the-counter...

  • Drug safety and regulation.  // BMJ: British Medical Journal (International Edition);7/2/2005, Vol. 331 Issue 7507, p4 

    Presents the author's views on issues regarding drug safety and regulation worldwide. Review of how numerous medical journals have been publishing editorials and news items relating to drug safety and regulation; View that the single biggest issue regarding drug safety has been the withdrawal of...

  • Propulsid patients to take new risk management tests.  // Medical Marketing & Media;Mar2000, Vol. 35 Issue 3, p18 

    Reports on revisions in the prescribing information for the drug Propulsid. Inclusion of initial electrocardiograms; Exclusion of patients with cardiac abnormalities; Agreement between the drug manufacturer, Janssen Pharmaceutica Inc. and the United States Food and Drug Administration.

  • FDA asserts authority to revoke Rx status.  // Employee Benefit News;Jun2003, Vol. 17 Issue 7, p34 

    Reports on the authority of the U.S. Food and Drug Administration (FDA) to revoke prescription status. Overview of the 2004 budget proposals of FDA; Drugs whose prescription status will be revoked.

  • The Curious Case of Off-Label Use. Dresser, Rebecca // Hastings Center Report;May/Jun2007, Vol. 37 Issue 3, p9 

    The article discusses the process of approving new drugs and devices for safety and effectivity by the U.S. Food and Drug Administration (FDA). Off-label prescribing of medical products occurs when clinicians give products to people with conditions not listed on the approval label and when they...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics